Cardiac regeneration by direct reprogramming in this decade and beyond.

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Molecular Biology

Background:

• Japan faces rising heart disease due to lifestyle changes and an aging population.
• Conventional treatments may be unsuitable for some patients.
• Stem cell therapy has limitations, leading to interest in direct cardiac reprogramming.

Purpose of the Study:

• To explore direct cardiac reprogramming as an alternative therapeutic strategy for myocardial regeneration.
• To identify key factors and conditions influencing fibroblast-to-cardiomyocyte transdifferentiation.
• To highlight challenges and potential improvements for human application.

Main Methods:

• Investigating the role of specific transcription factors (GMT, Mesp1, Myocd) in reprogramming.
• Examining the impact of inflammation, immune responses, and epigenetic modifiers (TET1, Bmi1).
• Evaluating strategies to enhance reprogramming efficiency: optimizing factors, culture conditions, and epigenetic regulation.

Main Results:

• GMT factors reprogram fibroblasts to cardiomyocytes in mice; human reprogramming requires additional factors.
• Inflammation and immune responses can impede reprogramming.
• Various factors (miR-133, TGF-β, Wnt, Akt1, Notch inhibitors, FGFs, VEGF, diclofenac) and epigenetic modifications influence efficiency.

Conclusions:

• Direct cardiac reprogramming shows promise for treating heart disease but requires significant improvement for human use.
• Further research is needed to elucidate molecular mechanisms and optimize the process.
• Advances in cardiac reprogramming could bring regenerative therapy closer to clinical reality.